Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
4 hedge funds and large institutions have $146K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2020 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
7% less capital invested
Capital invested by funds: $157K → $146K (-$11K)
43% less funds holding
Funds holding: 7 → 4 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$54K |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$20.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $93K | – | – | – |
|
|
SFM
2
Sphera Funds Management
Tel Aviv,
Israel
| $29K | – | – | – |
|
|
PC
3
PointState Capital
New York
| $22K | – | – | – |
|
|
CIA
4
Compass Ion Advisors
Conshohocken,
Pennsylvania
| $2K | – | – | – |
|
|
CAM
5
Cormorant Asset Management
Boston,
Massachusetts
| – | -$54K | -416,666 | Closed |
|
|
MWNA
6
Marshall Wace North America
New York
| – | -$20.9K | -125,400 | Closed |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$3K | -22,156 | Closed |
|
OTLKW Hedge Fund Activity: Q4 2020 in Review
4 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q4 2020, worth a combined $146K — down 7% from $157K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of OTLKW and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Cormorant Asset Management, exiting entirely with an estimated $54K sold.
- 4 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q4 2020, down from 7 in Q3 2020.
- Funds reported $146K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q4 2020, down 7% quarter-over-quarter.
- 0 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q4 2020 and 3 closed out, a net change of -3 holders.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q4 2020 was Cormorant Asset Management, an estimated $54K sold.
Based on aggregated 13F filings for Q4 2020.